![Potassium Channel Modulator Reduces Focal Onset Seizure Frequency in Clinical Trials - Practical Neurology Potassium Channel Modulator Reduces Focal Onset Seizure Frequency in Clinical Trials - Practical Neurology](https://core4.bmctoday.net/storage/images/220627_XEN1101_1656361529.jpg)
Potassium Channel Modulator Reduces Focal Onset Seizure Frequency in Clinical Trials - Practical Neurology
![EpilepsyNigeria on Twitter: "SEIZURE TYPES AND CLASSIFICATION: 1. Focal onset 2. Generalized Onset 3. Unknown Onset Please read Next Post.... #epilepsynigeria #EpilepsyFoundationOfNigeria #WeWantToTalkAboutEpilepsy #HaveYouSeenEpilepsy ... EpilepsyNigeria on Twitter: "SEIZURE TYPES AND CLASSIFICATION: 1. Focal onset 2. Generalized Onset 3. Unknown Onset Please read Next Post.... #epilepsynigeria #EpilepsyFoundationOfNigeria #WeWantToTalkAboutEpilepsy #HaveYouSeenEpilepsy ...](https://pbs.twimg.com/media/Db0Nub4X4AAitrG.jpg)
EpilepsyNigeria on Twitter: "SEIZURE TYPES AND CLASSIFICATION: 1. Focal onset 2. Generalized Onset 3. Unknown Onset Please read Next Post.... #epilepsynigeria #EpilepsyFoundationOfNigeria #WeWantToTalkAboutEpilepsy #HaveYouSeenEpilepsy ...
![Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study - The Lancet Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study - The Lancet](https://www.thelancet.com/cms/attachment/2070050435/2067854863/gr1.gif)